"We were already well funded to complete our clinical program and execute on our commercialisation strategy and these additional funds reinforce our strong financial position," said Tony Keating, CEO and Managing Director of ResApp.
About ResApp Health LimitedResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use cough sounds to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has adult and paediatric clinical studies underway at leading US and Australian hospitals with results demonstrating accurate diagnosis of pneumonia, asthma/reactive airways disease, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma, pneumonia and upper respiratory tract infections in adults. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as global aid and humanitarian organisations in the developing world.
For more information on ResApp, visit www.resapphealth.com.au
ContactsDr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au
Mr Brian Leedman Executive Director and
Vice President, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au
ResApp Health Limited published this content on 21 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 20 August 2017 23:47:01 UTC.
Original documenthttps://www.resapphealth.com.au/wp-content/uploads/2017/08/1703275.pdf
Public permalinkhttp://www.publicnow.com/view/D537A6BFE8705E544B63C2536401B54905950073